Keratoconjunctivitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Keratoconjunctivitis Clinical Trials Overview
The Keratoconjunctivitis clinical trial report consists of 1391 trials. The report provides an overview of the clinical trials, including top-line data. The data highlights the number of trial numbers and their average enrolment in top countries conducted across the globe. Furthermore, the clinical trials for Keratoconjunctivitis are elaborated by region, country (G7 & E7), phase, trial status, end points status, and sponsor type, in this report.
Key Regions | · Asia-Pacific
· Europe · North America · Middle East and Africa · South and Central America |
Key Countries | · The US
· China · Japan · South Korea · India · Italy · Spain · France · The UK · Germany |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Alcon Inc
· AbbVie Inc · Santen Pharmaceutical Co Ltd · Ora Inc · Bausch Health Companies Inc · Novartis AG · Others |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Keratoconjunctivitis Clinical Trials Segmentation by Regions and Countries
Asia-Pacific led the Keratoconjunctivitis clinical trials landscape with more than 35% of the clinical trials conducted there as of September 2023.
The key regions considered for Keratoconjunctivitis clinical trials analysis are Asia-Pacific, Europe, North America, Middle East and Africa, and South and Central America.
In a country-wise analysis, as of September 2023, the US accounted for the highest number of Keratoconjunctivitis clinical trials, followed by China and Japan.
G7 countries: Among the G7 (United States, United Kingdom, Germany, Canada, Japan, France, and Italy) countries, the US has the highest proportion of Keratoconjunctivitis to Ophthalmology clinical trials as of September 2023.
E7 countries: Among the E7 (China, India, Russia, Turkey, Brazil, Mexico, and Indonesia) countries, China has the highest proportion of Keratoconjunctivitis to Ophthalmology clinical trials as of September 2023.
Keratoconjunctivitis Clinical Trials Analysis by Regions, 2023 (%)
Buy Full Report for More Regional Insights into the Keratoconjunctivitis Clinical Trials
Keratoconjunctivitis Clinical Trials Segmentation by Sponsor Types
The key sponsor types for Keratoconjunctivitis clinical trials are company, institution, and the government. As of September 2023, the company sponsor type dominated the Keratoconjunctivitis clinical trials share, followed by institution.
Keratoconjunctivitis Clinical Trials Analysis by Sponsor Type, 2023 (%)
Buy Full Report for More Sponsor Type Insights into Keratoconjunctivitis Clinical Trials
Keratoconjunctivitis Clinical Trials - Competitive Landscape
In 2023, Alcon Inc. conducted the highest number of Keratoconjunctivitis clinical trials.
Some of the leading sponsors for Keratoconjunctivitis clinical trials are:
- Alcon Inc
- AbbVie Inc
- Santen Pharmaceutical Co Ltd
- Ora Inc
- Bausch Health Companies Inc
- Novartis AG
Keratoconjunctivitis Clinical Trials Analysis by Sponsors, 2023 (%)
Buy Full Report to Know More About the Leading Players of Keratoconjunctivitis Clinical Trials Download a Free Sample Report
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies concerning investment.
- Helps identify prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps identify key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
AbbVie Inc
Santen Pharmaceutical Co Ltd
Ora Inc
Bausch Health Companies Inc
Novartis AG
Otsuka Holdings Co Ltd
Laboratoires Thea SA
Innovative Medical Products Inc
Viatris Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of Keratoconjunctivitis clinical trials?
Asia-Pacific accounted for the highest number of Keratoconjunctivitis clinical trials as of September 2023.
-
Which country conducted the highest number of Keratoconjunctivitis clinical trials?
The US conducted the highest number of Keratoconjunctivitis clinical trials as of September 2023.
-
Which sponsor type was the most prominent in the Keratoconjunctivitis clinical trials?
Company was the most prominent sponsor type for Keratoconjunctivitis clinical trials.
-
Who are the leading sponsors of Keratoconjunctivitis clinical trials?
Some of the leading sponsors of Keratoconjunctivitis clinical trials are Alcon Inc., AbbVie Inc., Santen Pharmaceutical Co. Ltd., Ora Inc., Bausch Health Companies Inc., and Novartis AG, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.